Tag: Weight Loss
Eli Lilly Says Its New Weight-Loss Drug, Zepbound, Is Now Available
Tirzepatide, the active ingredient in Zepbound, had already been approved by the FDA as a treatment for type 2 diabetes
AHA: Semaglutide Cuts Risk for CVD Events in Patients Without Diabetes
Findings seen over three years in adults with preexisting cardiovascular disease and overweight or obesity
FDA Approves New Diet Drug Zepbound, a Version of the Diabetes Med Mounjaro
Zepbound works by activating hormone receptors in the body to reduce appetite and food intake
Tirzepatide Tied to Substantial Additional Weight Loss After Lifestyle Intervention
Authors say additional benefits seen for other health-related measures
FDA Investigating Hospitalizations Linked to Counterfeit Ozempic
Novo Nordisk has said that it is working with the FDA to make consumers aware of the counterfeits
Presenting Weight Loss Treatment as Positive Opportunity Is Beneficial
Uptake of treatment and weight change greater when referral is presented as good news relative to neutral news
Time-Restricted Eating Effective for Weight Loss, Lowering HbA1c
TRE without calorie counting is effective and yields significant reduction in body weight at six months
Weight Loss-Driven Remission of Prediabetes Tied to Lower Type 2 Diabetes Risk
Those reversing prediabetes show improvement in insulin sensitivity but not greater weight loss than those not achieving remission
GI Adverse Events Increased With Use of GLP-1 Agonists for Weight Loss
Increased risks seen for pancreatitis, bowel obstruction, and gastroparesis, but not for biliary disease
Durable Reductions in HbA1c, Body Weight Seen With Semaglutide
Real-world study shows greater reductions in HbA1c and body weight for patients with proportion of days covered ≥60 percent
